Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPIC-PRP: LR-PRP vs LP-PRP vs Placebo for Epicondylitis
NCT06040203Recruiting
- Sponsor
- Istituto Ortopedico Rizzoli
- Start
- Mar 2023
- Primary completion
- Mar 2027
- Modality
- Adipose-derived MSCs, Bone Marrow MSCs
- Countries
- 1
01
Overview
Randomised, double-blind trial of platelet-rich plasma in Lateral Epicondylitis (LET) (3 arms), sponsored by Istituto Ortopedico Rizzoli. Primary endpoint: Patient-rated Tennis Elbow Evaluation at 6 months. Started Mar 2023; status: recruiting.
02
Drugs
platelet-rich plasma
03
Conditions
Lateral Epicondylitis (LET)
Beyond the preview
Go deeper on NCT06040203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06040203.